LL-37: Benefits, Evidence, Dosing & Side Effects
Disclaimer: This article is for educational purposes only and does not constitute medical advice. LL-37 is not FDA-approved for therapeutic use and is available only as a research peptide in most jurisdictions. Consult with a qualified healthcare provider before considering LL-37 supplementation, especially if you have autoimmune conditions, active malignancies, or are taking immunosuppressive medications.
Overview
LL-37 is a 37-amino acid antimicrobial peptide and the only known member of the cathelicidin family found in humans. Your body naturally produces LL-37 through neutrophils, epithelial cells, and keratinocytes as part of your innate immune system. Beyond its antimicrobial role, LL-37 has attracted significant research interest for its immunomodulatory properties, wound-healing capabilities, and potential applications in treating chronic wounds, skin infections, and inflammatory conditions.
The peptide operates through multiple biological pathways, making it a uniquely versatile compound for research. While animal models and mechanistic studies show considerable promise, the human clinical evidence remains limited, with most available data derived from small Phase I/II trials and observational studies rather than large-scale randomized controlled trials.
How It Works: Mechanism of Action
LL-37 exerts its biological effects through three primary mechanisms:
Antimicrobial Activity
LL-37 disrupts bacterial, fungal, and viral membranes through electrostatic interactions with negatively charged phospholipids. This causes membrane permeabilization and direct microbial cell death. The peptide has demonstrated in-vitro efficacy against 38 bacterial species, 16 fungal species, and 16 viral species through multiple mechanisms including membrane rupture, oxidative stress, and biofilm suppression.
Immunomodulation
The peptide acts as an immunomodulatory agent by binding to pattern recognition receptors and activating TLR4 signaling pathways. This activation promotes chemokine release and recruits immune cells—including neutrophils and monocytes—to sites of infection. Importantly, LL-37 also functions as a specific transporter of cGAMP, enabling STING-dependent interferon responses and antiviral immunity.
Wound Healing and Tissue Repair
LL-37 stimulates wound healing through EGFR transactivation, VEGF upregulation, and promotion of keratinocyte migration and proliferation. It also enhances tissue repair through TFEB-dependent autophagy pathways, making it particularly relevant for managing chronic wounds and injury recovery.
Evidence by Health Goal
Fat Loss — Tier 2 Evidence
LL-37 shows plausible mechanisms for reducing fat accumulation and hepatic steatosis in animal models, with altered expression observed in obesity. However, human efficacy remains unproven with no randomized controlled trials testing LL-37 for weight loss outcomes.
Key Findings:
- Lentiviral cathelicidin overexpression in high-fat diet-fed diabetic mice reduced hepatic steatosis and fat mass, with decreased mesenteric fat and hepatic CD36 expression
- Serum cathelicidin levels were significantly elevated in non-diabetic and prediabetic obese patients compared to normal BMI controls
Bottom Line: Animal evidence is promising, but human studies are lacking.
Muscle Growth — Tier 1 Evidence
LL-37 has not been demonstrated to promote muscle growth in any available research. The peptide functions primarily as an antimicrobial and immunomodulatory agent—no human or animal studies report effects on skeletal muscle hypertrophy or strength gains.
Key Findings:
- Salivary LL-37 levels did not change after acute exercise at any intensity (35%, 55%, or 75% VO₂max) or duration (30, 60, or 90 minutes) in humans (n=14, randomized controlled trial)
- LL-37 promotes wound healing in diabetic mice, but no muscle phenotype assessment was performed
Bottom Line: No evidence supports LL-37 for muscle growth.
Injury Recovery — Tier 3 Evidence
LL-37 shows probable efficacy for injury recovery based on human studies and consistent animal data, though evidence is limited to one randomized controlled trial and small observational cohorts.
Key Findings:
- LL-37 cream increased granulation index in diabetic foot ulcers versus placebo on days 7, 14, 21, and 28 (p=0.031, 0.009, 0.006, and 0.037 respectively) in a human randomized controlled trial
- LL-37 gene expression increased 4.3–5.1 fold in human gingival tissue one month post-scaling/root planing (n=30, p<0.001)
Bottom Line: Solid mechanistic support with emerging human evidence, particularly for wound healing.
Joint Health — Tier 2 Evidence
LL-37 is elevated in joint tissues and synovial fluid of patients with joint infections and inflammatory arthritis, suggesting a role in joint pathology. However, no human studies demonstrate that LL-37 supplementation improves joint health or reduces symptoms.
Key Findings:
- LL-37 in synovial fluid achieved AUC 0.875 for diagnosing periprosthetic joint infection (n=15 infected, 20 controls), superior to several other biomarkers
- Anti-carbamylated LL-37 antibodies in rheumatoid arthritis synovial fluid correlated with radiologic bone erosion scores, suggesting LL-37 modification drives pathogenic bone resorption
Bottom Line: Useful as a diagnostic marker, but therapeutic potential unproven.
Anti-Inflammation — Tier 2 Evidence
LL-37 shows anti-inflammatory effects primarily in animal models and cell culture studies, with emerging human observational evidence. However, no human randomized controlled trials demonstrate therapeutic efficacy, and the role appears context-dependent—sometimes protective, sometimes pro-inflammatory.
Key Findings:
- In sepsis-induced lung injury in mice, LL-37 treatment suppressed LPS-induced TNF-α, IL-18, and IL-1β release and reversed autophagy impairment, improving survival outcomes
- In psoriasis patients (n=50), serum LL-37 was significantly elevated compared to controls (n=33, p<0.001) and positively correlated with pro-inflammatory cytokines IFN-γ, IL-17, and IL-22
Bottom Line: Context matters; elevation in inflammatory conditions suggests a complex, bidirectional relationship.
Cognition — Tier 2 Evidence
LL-37 shows mixed and inconclusive evidence for cognition. One human observational study found higher LL-37 associated with cognitive decline in older adults, while mechanistic reviews suggest potential neuroprotective roles through gut-brain axis pathways.
Key Findings:
- Higher serum LL-37 at baseline was associated with greater longitudinal cognitive decline (MMSE ≥3 point decrease) in older adults with memory complaints: OR=2.11 (95% CI 1.32–3.38) (n=357, 2-year follow-up)
- The high LL-37 group showed significantly larger increases in neurofilament light and pTau181, markers of neurodegeneration
Bottom Line: Elevated LL-37 may be a marker of neurodegeneration rather than a beneficial intervention.
Mood & Stress — Tier 1 Evidence
LL-37 has not been demonstrated to improve mood or stress in any human studies. Available evidence consists entirely of mechanistic studies in animals and cells, with no human trials examining mood, anxiety, depression, or stress reduction.
Key Findings:
- Lower serum LL-37 levels were found in schizophrenia patients (n=35) compared to bipolar disorder patients (n=40), p=0.006—but this was a biomarker correlation, not a treatment study
- Sleep deprivation aggravated LL-37-induced rosacea-like phenotypes in mice (animal model only, no mood measures)
Bottom Line: No human efficacy evidence.
Sleep — Tier 1 Evidence
LL-37 has no demonstrated efficacy for improving sleep in humans. Evidence consists of one pilot randomized controlled trial measuring LL-37 as a secondary outcome of vitamin D supplementation, and two studies showing LL-37 involvement in rosacea-sleep associations in animal models.
Key Findings:
- In rosacea patients (n=608), poor sleep quality (PSQI >5) was associated with LL-37-induced rosacea phenotypes (OR 1.847, 95% CI 1.332–2.570)
- In LL-37-injected mice, circadian rhythm disruption suppressed circadian clock proteins and promoted pro-inflammatory M1 macrophage polarization
Bottom Line: No evidence supports LL-37 for sleep improvement.
Longevity — Tier 2 Evidence
LL-37 shows plausible mechanisms for longevity-relevant processes (autophagy, inflammation, cardiovascular protection) but lacks direct human evidence of lifespan extension or clinical longevity outcomes.
Key Findings:
- In humans with acute myocardial infarction (n=1,102), elevated serum LL-37 (Tertile 3) was associated with reduced ischemic cardiovascular events: HR 0.651 (95% CI 0.433–0.981, p=0.040)
- In mice with myocardial ischemia/reperfusion injury, CRAMP (mouse LL-37 homolog) injection reduced infarct size and cardiomyocyte apoptosis; knockout mice showed exacerbated injury
Bottom Line: Cardioprotective mechanisms documented in animals; human evidence is observational.
Immune Support — Tier 2 Evidence
LL-37 demonstrates broad antimicrobial and immunomodulatory properties in mechanistic and animal studies, but human efficacy for immune support remains unproven.
Key Findings:
- LL-37 exhibits in-vitro efficacy against 38 bacterial species, 16 fungal species, and 16 viral species through multiple mechanisms
- LL-37 functions as a specific transporter of cGAMP, enabling STING-dependent interferon responses; vitamin D3 and sodium butyrate promote endogenous LL-37 expression
Bottom Line: Robust mechanistic support; human efficacy trials lacking.
Energy — Tier 1 Evidence
LL-37 has not been studied as an energy-enhancing agent in any available research. Evidence examining LL-37's antimicrobial and inflammatory effects suggests mitochondrial impairment rather than enhancement.
Key Findings:
- LL-37 triggers release of pro-apoptotic factors and cytochrome C from mitochondria in human osteoblast cells
- LL-37 accumulates in mitochondria within 20 minutes of exposure, leading to mitochondrial membrane permeabilization
Bottom Line: No evidence supports energy enhancement; potential for mitochondrial impairment.
Skin & Hair — Tier 2 Evidence
LL-37 shows mechanistic promise for skin and hair health through antimicrobial, wound-healing, and immunomodulatory pathways. Human efficacy evidence is limited to observational studies and one small randomized controlled trial.
Key Findings:
- Reintroduction of antimicrobial coagulase-negative Staphylococcus strains producing LL-37-synergistic peptides decreased S. aureus colonization in human atopic dermatitis subjects
- LL-37 serum levels were significantly elevated in psoriasis patients (mean 11.3 ± 2.3 vs controls 2.8 ± 1.5, p<0.001) and positively correlated with disease severity
Bottom Line: Wound healing supported; use in inflammatory skin conditions requires caution.
Gut Health — Tier 2 Evidence
LL-37 shows plausible mechanisms for supporting gut health through antimicrobial and barrier-protective effects. Human evidence remains limited to small observational studies and one infant randomized controlled trial.
Key Findings:
- In infants with colic (n=80, RCT), BB-12 probiotic treatment increased fecal LL-37 and HBD-2 levels, with ≥50% reduction in daily crying duration by week 2
- In a heat stroke rat model, LL-37 treatment attenuated intestinal injury, reduced systemic inflammation, and improved survival rate
Bottom Line: Preliminary evidence in neonates; larger human trials needed.
Heart Health — Tier 3 Evidence
LL-37 shows probable benefit for heart health based on human observational studies demonstrating associations between higher LL-37 levels and reduced cardiovascular events after myocardial infarction.
Key Findings:
- High baseline LL-37 levels in post-STEMI patients (n=302) predicted lower MACE at 3 years: 12.6% versus 29.1% in the low LL-37 group (HR 0.390, 95% CI 0.227–0.669, p<0.001)
- Higher LL-37 independently predicted lower all-cause mortality post-STEMI: HR 0.324 (95% CI 0.119–0.879, p=0.027) in multivariable Cox regression
Bottom Line: Observational evidence supports cardiovascular protection; randomized trials needed.
Liver Health — Tier 3 Evidence
LL-37 shows probable protective effects in liver disease based on multiple human observational studies and animal models with evidence for anti-inflammatory and regenerative mechanisms.
Key Findings:
- In cirrhotic patients, vitamin D supplementation increased LL-37 expression 2,000-fold in peritoneal macrophages compared to untreated controls
- CRAMP knockout mice developed more severe liver injury, greater intrahepatic fat accumulation, and enhanced fibrosis progression in multiple injury models
Bottom Line: Mechanistic support and animal evidence solid; human trials absent.
Hormonal Balance — Tier 2 Evidence
LL-37 shows plausible hormonal modulatory effects in observational human studies and animal models, but efficacy is not proven. Evidence demonstrates reciprocal interactions between LL-37 and steroid hormones rather than confirming that supplementation improves hormonal health.
Key Findings:
- In sepsis patients (n=80, RCT), high-dose vitamin D3 (50,000 IU) significantly increased serum LL-37 levels compared to low-dose (5,000 IU), p<0.001
- In macrophage cultures, DHEA increased LL-37 expression while cortisol suppressed it; in adrenal cells, LL-37 (5–15 µg/ml) reduced both cortisol and DHEA synthesis in a dose-dependent manner
Bottom Line: Complex bidirectional relationships; insufficient evidence for therapeutic use.
Sexual Health — Tier 2 Evidence
LL-37 has demonstrated spermicidal and antimicrobial activity against sexually transmitted pathogens in laboratory and animal studies, but human efficacy for sexual health remains unproven.
Key Findings:
- LL-37 inhibited mouse and human sperm fertilizing ability in-vitro at physiological concentrations (2–30 minute exposure, up to 10.8 µM), affecting motility and acrosome integrity
- In female mice, LL-37 administered intravaginally produced contraceptive effects with 100% reversibility of fecundity after single administration
Bottom Line: Contraceptive potential documented in animals; no human efficacy studies.
Athletic Performance — Tier 2 Evidence
LL-37 levels change in response to exercise in humans, but there is no evidence that LL-37 supplementation or elevation improves athletic performance.
Key Findings:
- Salivary LL-37 concentrations and secretion rates increased significantly following 2.5 hours of prolonged cycling at approximately 60% VO₂max in humans (n=12, p<0.05)
- LL-37 did not change after acute cycling exercise at multiple intensities and durations in another cohort (n=14)
Bottom Line: LL-37 is a salivary antimicrobial peptide that responds variably to exercise; no performance benefit demonstrated.
Dosing Protocols
LL-37 is available through three primary routes of administration, each with distinct dosing parameters:
Injection
- Dosage: 100–500 mcg once daily
- Administration: Subcutaneous or intramuscular injection
- Considerations: Most potent delivery method; associated with injection site reactions
Topical Application
- Dosage: 0.1–1% concentration formulation applied to affected area
- Frequency: Twice daily
- Considerations: Direct delivery to skin lesions; minimal systemic absorption
Nasal
- Route: Intranasal application (specific dosing varies)
- Frequency: Typically once or twice daily
- Considerations: Non-invasive delivery with potential for systemic effects
Important Note: